Universität zu Köln

Roen, A., Laut, K., Pelchen-Matthews, A., Borodulina, E., Caldeira, L., Clarke, A., Clotet, B., Monforte, A. d'Arminio, Faetkenheuer, G., Gatell Artigas, J. M., Karpov, I., Kuznetsova, A., Kyselyova, G., Mozer-Lisewska, I., Mulcahy, F., Ragone, L., Scherrer, A., Uzdaviniene, V., Vandekerckhove, L., Vannappagari, V., Ostergaard, L. and Mocroft, A. (2018). Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Med., 19 (4). S. 252 - 261. HOBOKEN: WILEY. ISSN 1468-1293

Full text not available from this repository.

Abstract

ObjectivesFive to eight per cent of HIV-positive individuals initiating abacavir (ABC) experience potentially fatal hypersensitivity reactions (HSRs). We sought to describe the proportion of individuals initiating ABC and to describe the incidence and factors associated with HSR among those prescribed ABC. MethodsWe calculated the proportion of EuroSIDA individuals receiving ABC-based combination antiretroviral therapy (cART) among those receiving cART after 1 January 2009. Poisson regression was used to identify demographic, and current clinical and laboratory factors associated with ABC utilization and discontinuation. ResultsBetween 2009 and 2016, of 10 076 individuals receiving cART, 3472 (34%) had ever received ABC-based cART. Temporal trends of ABC utilization were also heterogeneous, with 28% using ABC in 2009, dropping to 26% in 2010 and increasing to 31% in 2016, and varied across regions and over time. Poisson models showed lower ABC utilization in older individuals, and in those with higher CD4 cell counts, higher cART lines, and prior AIDS. Higher ABC utilization was associated with higher HIV RNA and poor renal function, and was more common in Central-East and Eastern Europe and lowest during 2014. During 779 person-years of follow-up (PYFU) in 2139 individuals starting ABC after 1 January 2009, 113 discontinued ABC within 6 weeks of initiation for any reason [incidence rate (IR) 14.5 (95% confidence interval (CI) 12.1, 17.5) per 100 PYFU], 13 because of reported HSR [IR 0.3 (95% CI 0.1, 1.0) per 100 PYFU] and 35 because of reported HSR/any toxicity [IR 4.5 (95% CI 3.2, 6.3) per 100 PYFU]. There were no factors significantly associated with ABC discontinuation because of reported HSR/any toxicity. ConclusionsABC remains commonly used across Europe and the incidence of discontinuation because of reported HSR was low in our study population.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Roen, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Laut, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pelchen-Matthews, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borodulina, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Caldeira, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Clarke, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Clotet, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Monforte, A. d'Arminio UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gatell Artigas, J. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Karpov, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuznetsova, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kyselyova, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mozer-Lisewska, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mulcahy, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ragone, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Scherrer, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Uzdaviniene, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vandekerckhove, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vannappagari, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ostergaard, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mocroft, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-191732
DOI:	10.1111/hiv.12573
Journal or Publication Title:	HIV Med.
Volume:	19
Number:	4
Page Range:	S. 252 - 261
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1468-1293
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC KIDNEY-DISEASE; ANTIRETROVIRAL THERAPY; HIV; COMBINATION; RECHALLENGE; HLA-B-ASTERISK-5701; ASSOCIATION; ZIDOVUDINE; TENOFOVIR; SAFETY Multiple languages Infectious Diseases Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19173